Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion
Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients
Gregory M Georgiadis MD
200 participants
Aug 30, 2017
INTERVENTIONAL
Conditions
Summary
Tranexamic Acid (TXA) is an antifibrolytic medication used in total hip and knee arthroplasty to reduce the need for intraoperative and postoperative blood transfusions. Limited research is available on its use in hip fracture patients. We hypothesize that the use of TXA preoperatively, perioperatively, and postoperatively will decrease blood loss and need for blood transfusion postoperatively.
Eligibility
Inclusion Criteria3
- Over the age of 60 years
- Hip fracture requiring surgical intervention
- Signs consent and agrees to participate
Exclusion Criteria14
- Under the age of 60
- Does not sign consent or refuses participation
- Known hypersensitivity to tranexamic acid
- Multiple acute fractures
- Creatinine clearance <30
- History of seizures
- Active hormone therapy
- History of coagulation abnormality
- History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the last year or history or recurrent DVT/PE
- Myocardial infarction (MI) and/or stents within the past year
- History of intracranial hemorrhage
- Acquired defective color vision
- Patients admitted directly to nursing units or surgery without stay in the Emergency Center
- Patients who sustain fracture while hospitalized at ProMedica Toledo Hospital
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Tranexamic acid is an antifibrinolytic used to control bleeding
Saline solution is used as the placebo comparator
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03063892